yikes

Houston again plummets on list of best places to live in new national report

Houston didn't even crack the top 100 in the new list. Photo by Alisa Matthews on Unsplash

In a surprise turn of events, Houston has fallen from grace in U.S. News and World Report's "Best Places to Live" ranking for 2023-2024.

Last year, Houston ranked No. 59 on the annual report — not surprising, considering all the Newstonians. However, the Bayou City plummeted to a shocking No. 140. Two years ago, the city ranked as No. 39, so this year's report represents a series of slips for Houston.

But why? According to the report: "A paycheck goes further in Houston than it does in other major metro areas, with affordable housing and free or cheap attractions like biking along Buffalo Bayou and exploring the 7,800-acre George Bush Park. The affordability of this region, which is located in southeastern Texas and home to more than 7 million residents in the metro area, is attracting new people from across the country and around the world."

The report takes a look at several different metrics to determine their rankings, including quality of life, housing affordability, desirability, and job market strength.

Somehow, Houston scored a mere 5.6 out of 10 in the livability score. By the numbers (and out of a perfect 10), Houston scored a 6 for desirability, 6.3 for value, 5.5. for job market, a surprising 5 for quality of life, and 5.9 for net migration.

It gets worse: Houston ranks as only No. 10 on the report's Best Place to Live in Texas list for 2023.

Texas overall saw a major drop. Austin, previously the No. 1 place to live in America for three consecutive years from 2017 to 2019, lands at No. 40 overall this year. Austin managed to hang on to its title of the Best Place to Live in Texas for 2023, with San Antonio at No. 2, and Dallas-Fort Worth taking No. 3. Rounding out the top five is Killeen in No. 4, and El Paso at No. 5.

Here's how other Texas cities faired in 2023's Best Places to Live report:

  • No. 103 – San Antonio, down from No. 83 last year
  • No. 113 – Dallas-Fort Worth, down from No. 32 last year
  • No. 122 – Killeen, down from No. 108 last year
  • No. 128 – El Paso, down from No. 124 last year
  • No. 131 – Beaumont, down from No. 109 last year
  • No. 132 – Corpus Christi, up from No. 133 last year
  • No. 134 – Brownsville, unchanged from last year
  • No. 137 – McAllen, up from No. 138 last year
  • No. 140 – Houston, down from No. 59 last year

The full report can be found on U.S. News and World Report's website.

------

This article originally ran on CultureMap.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted